🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Humana (HUM) Hits 52-Week High On Solid Q2, Raised Outlook

Published 08/29/2017, 10:36 PM
Updated 07/09/2023, 06:31 AM
US500
-
AET
-
HUM
-
UNH
-
ABCO
-

On Aug 29, Humana Inc. (NYSE:HUM) hits a 52-week high of $255.91. The improvement is believed to have been driven by strong second-quarter results, guidance raise and the recent completion of accelerated share buyback.

Notably, the stock has surged 43% in the last year, almost in line with the industry’s rally of 42% but significantly outperforming the S&P 500 index’s rise of 12.2%.

In fact, investors are optimistic on this Zacks Rank #3 (Hold) company’s strong second-quarter earnings that topped Zacks Consensus Estimate by 13.3%. This uptick was owing to solid performance by both the Medicare Advantage business segment and Retail segment.

The company’s raised guidance (for the second time this year) is also encouraging. Humana now expects 2017 adjusted earnings per share of $11.50, to be up from the previous guidance of at least $11.10 per share. The latest guidance also reflects 20% increase in earnings compared with 2016. Operating cash flow increased by approximately $200 million, primarily owing to a better financial performance.

Interestingly, an upbeat guidance instills confidence in the company’s ability to perform well in a highly regulated and competitive industry.

Consequently, the company announced a strong outlook for its Medicare business, one of its most significant growth drivers. It expects approximately 74% of its Medicare members to be in 4-Star or higher plans, for the year 2018, which compares favorably to its previous forecast of 37%.

Going forward, Humana’s anticipates to book 2017 pre-tax earnings of approximately $85 million in its Indiividual Commercial segment compared with the previous expectation of a full-year loss of approximately $45 million. The reversal in this segment is expected to be driven by lower-than-anticipated medics cost for the exchange enrollees.

Investors also viewed favorably the timely completion of $1.5 billion of accelerated share buyback plan announced in the first quarter.

In fact, another leading health insurer UnitedHealth Group Inc. (NYSE:UNH) also touched a 52-week high on the same day, followed by the announcement that The Advisory Board Company’s (NASDAQ:ABCO) health care business will join Optum, which is the company’s health services unit.

A better-ranked stock in the same space include Aetna Inc. (NYSE:AET) holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Aetna is one of the largest health benefits companies that topped estimates in each of the last four quarters with an average positive surprise of 19%.

4 Surprising Tech Stocks to Keep an Eye On

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.

See Stocks Now>>



Aetna Inc. (AET): Free Stock Analysis Report

Humana Inc. (HUM): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

The Advisory Board Company (ABCO): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.